Revisit Every OncLive On Air Episode From April 2026

In case you missed any, below is a recap of the episodes of OncLive On Air^® that aired in April 2026. Check out our podcast page for a full episode lineup and to stay up to date with all the latest releases!

Optimizing TKI Sequencing and Ponatinib Dosing Strategies in CML: With Quinto Gesiotto, MD

In this episode of OncLive On Air, Quinto Gesiotto, MD, of Tampa General Hospital in Florida, discussed the evolving role of TKIs in the management of chronic myeloid leukemia (CML), dosing patterns for ponatinib (Iclusig) in patients with CML, emerging data with novel agents, and genetic mutations beyond BCR-ABL1 T315I the could drive the personalization of treatment sequencing and improve risk stratification going forward.

“The bottom line here is that we can increase the efficacy of [ponatinib] by starting at the higher dose, and also decrease the toxicity and dangerous [adverse] effects [AEs] by decreasing down to 15 mg daily when indicated,” Gesiotto said.

How a Passion for Justice Leads the Fight in Tobacco Litigation: With D. Ross Camidge, MD, PhD; and Alex Alvarez

In this episode of How This Is Building Me, host D. Ross Camidge, MD, PhD, sat down with Alex Alvarez, a lawyer specializing in tobacco litigation and jury selection, to highlight Alvarez’s career path, which has included roles as a Miami police officer and a civil trial lawyer focusing on corporate malfeasance within the tobacco industry.

“[The tobacco executives] had known for decades that smoking was harming their customers, and they…kept hiding it,” Alvarez explained.

“One of the things I’ve learned from working with you and other lawyers is, as an academic, we think there’s the truth, and anything that isn’t the truth is, is not the truth,” Camidge shared. “Whereas the reality of the trial is the only people you have to convince are 12 people on the jury. It’s much more about emotive arguments.”

Lifestyle Interventions, Exercise Programs, and Metabolic Medications Are Key to Holistic Breast Cancer Survivorship: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

In this episode of Breast Cancer Briefing, host Sara Nunnery, MD, MSCI, of Tennessee Oncology in Nashville, welcomed Neil M. Iyengar, MD, of the Winship Cancer Institute of Emory University in Atlanta, Georgia, to talk through lifestyle and medical interventions relevant to breast cancer survivorship, including the rising use of GLP-1 receptor agonists to manage metabolic health.

“I feel passionate that we can use lifestyle interventions precisely and as medical therapy,” Iyengar shared. “We’ve taken a drug development paradigm to develop precision lifestyle interventions. What I mean by precision lifestyle interventions is that I don’t think that there is a one-size-fits-all approach. We should not be recommending the same diet for every single person.”

“It can be a struggle to feel like we’re giving [a patient] a drug to try to improve their outcome, but then we’re also potentially giving them adverse effects that might compromise that outcome,” Nunnery added.

The Intricacies of Approved Therapies Pose Questions for CLL Management: With Mazyar Shadman, MD, MPH

In this episode, Mazyar Shadman, MD, MPH, of Fred Hutchinson Cancer Center in Seattle, Washington, spotlighted the clinical implications of findings from a post hoc indirect comparison evaluating zanubrutinib (Brukinsa) vs acalabrutinib (Calquence) plus venetoclax (Venclexta) in patients with treatment-naive chronic lymphocytic leukemia.

“Patients care about efficacy,” Shadman stated. “This study is a source of information that I share with patients who are more focused on efficacy.”

How Strategic Partnerships Expand the Reach of Cancer Research: With D. Ross Camidge, MD, PhD; and Dajan O’Donnell, PhD

In this episode of How This Is Building Me, Camidge was joined by Dajan O’Donnell, PhD, of Cancer Research Society in Montreal, Canada, to discuss O’Donnell’s career, highlights of which have included building a research unit, creating a molecular registry for patients with cancer, and organizing funding for a vast array cancer research.

“What doesn’t kill you, makes you stronger,” O’Donnell shared. “I was [at] a fork in my career. I was finishing at one pharmaceutical company. I could have gone back to another pharmaceutical company, but I decided to explore more the not-for-profit and cancer research [field].”

“Your impact has been incredible, and it’s been a delight to watch,” Camidge said to O’Donnell.

Evolving Research Puts a Focus on GLP-1 Agonist Use in Breast Cancer: With Sara Nunnery, MD, MSCI; and Neil M. Iyengar, MD

In part 2 of this discussion, Nunnery and Iyengar dove deeper into the evolving integration of GLP-1 agonists into the treatment paradigm for patients with breast cancer.

“I worry about initiating a GLP-1 receptor agonist in patients who are receiving or starting chemotherapy,” Iyengar said. “We don’t know about the interactions; we don’t know if the adverse effects will compound. The last thing I want to do is cause a patient more AEs like gastric or gastrointestinal toxicities, that will decrease our ability to deliver chemotherapy effectively.”

“I’ve had a couple primary care physicians reach out to me for letters to give their patients’ insurance companies saying that we think [GLP-1 receptor agonists are] safe,” Nunnery explained. “We see insurance companies deny them for people who have had a cancer history.”

RAS/MAP Kinase Pathway Targeting Makes Strides in Gynecologic Cancer Management: With Ursula A. Matulonis, MD; and Elizabeth H. Stover, MD, PhD

In this episode of From Discovery to Delivery: Charting Progress in Gynecologic Oncology, host Ursula A. Matulonis, MD, of Dana-Farber Cancer Institute, sat down with Elizabeth H. Stover, MD, PhD, of Dana-Farber Cancer Institute, to spotlight the relevance of the RAS/MAP kinase pathway in the development and management of gynecologic cancers.

“For years, [RAS] was an undruggable oncogene,” according to Stover. “But more recently, the small molecule inhibitors that directly inhibit KRAS have been developed and have shown significant clinical effects in areas such as non–small cell lung cancer, pancreatic cancer, and colorectal cancer. We’d like to be able to bring some of those molecules over to gynecologic cancers.”

“The [RAS/MAPK] pathway [that was] known to be undruggable is now potentially druggable,” Matulonis summarized.

Localized Bladder Cancer 2026 UPDATE

In this episode of Two Onc Docs, hosts Samantha A. Armstrong, MD, of Indiana University Health in Indianapolis, and Karine Tawagi, MD, of the University of Illinois in Chicago, sat down to discuss the histology of and updates to the evolving treatment paradigm for localized bladder cancer.

“It’s incredibly important, when looking at the pathology, that there is muscle on the specimen,” Armstrong noted. “If they ever give you a vignette where there is no muscularis on the specimen, the answer will always be repeat transurethral resection of bladder tumor.”

“In the next few years, if you’re stumped on a bladder question on your boards, guess enfortumab vedotin-ejfv [Padcev] plus pembrolizumab [Keytruda], because it’s in almost every category,” Tawagi explained.

How Surgical Determination Intersects With Human Connection: With D. Ross Camidge, MD, PhD; and Robert A Meguid, MD, MPH, FACS

In this episode of How This Is Building Me, Camidge was joined by Robert A Meguid, MD, MPH, FACS, of the University of Colorado in Aurora, to talk through Dr Meguid’s medical career, which has included a focus on surgical outcomes and risk analysis, pioneering robotic-assisted surgical techniques, and a reinforced commitment to patient-centered care following a personal medical event.

“You have no idea what the person in front of you has gone through,” Meguid emphasized. “Just looking at them doesn’t tell you their story. You don’t know what barriers they’ve overcome. You don’t know what barriers they’re subjected to. You don’t know what their preferences and beliefs are.”

“That grit of putting one foot in front of the other, especially when it takes tremendous effort, is what we can all aspire to,” Camidge said of Meguid.

ADCs Change Treatment Paradigms and Challenge Standard AE Management Protocols in TNBC: With Sara Nunnery, MD, MSCI; and Irene Morae Kang, MD

In this episode of Breast Cancer Briefing, Nunnery welcomed Irene Morae Kang, MD, of City of Hope Orange County in Irvine, California, to discuss updates to the triple-negative breast cancer (TNBC) treatment armamentarium, including the role of PD-L1 expression, the use of immunotherapy, the emergence of antibody-drug conjugates, and treatment-related toxicities that should guide clinical decision-making.

“For metastatic TNBC, even when we’re in the stages of just starting the first treatment, OS in this population is not long,” Kang stated. “On average, it’s less than 2 years. Coupled with that, despite effective first-line treatments, some patients don’t make it to a second line of therapy, which is scary.”

“We don’t want to lose our patients that early,” Nunnery said. “If we can give our best drug first and give them more time, that’s always what we’re hoping for, rather than saving something for later, because you don’t know about later.”

Treatment Advances in Relapsed SCLC Introduce New Options and Clinical Workflows: With Alissa Cooper, MD

In this episode, Alissa Cooper, MD, of Dana-Farber Cancer Institute, talked through research and treatment advances for relapsed small cell lung cancer (SCLC), including the FDA approval of tarlatamab-dlle (Imdelltra), biomarker explorations, real-world treatment sequencing, and decision-making at the point of relapse.

“Arguably the biggest impact that has changed SCLC management has been the approval of the drug tarlatamab, which is a DLL3-targeting T-cell engager,” Cooper emphasized. “It was FDA approved in May 2024 and has been in regular use since then.”

FES-PET/CT Reshapes Treatment Planning in Lobular Breast Cancer and Beyond: With Megan Kruse, MD

In this episode, Megan Kruse, MD, of Cleveland Clinic in Ohio, spotlighted considerations for the use of FES-PET/CT in invasive lobular breast carcinoma, including how this imaging modality may guide treatment changes and what future research may reveal about the use of this modality in early-stage disease and monitoring response to endocrine therapy.

“When I think about using novel imaging techniques like FES-PET/CT, the hope is that you can clear up uncertainty for patients and make a clear treatment path forward,” Kruse summarized. “It may particularly help in times where we know that there are spots on traditional imaging that are concerning for cancer that we can’t biopsy because of safety or logistic factors, or if the regular scans don’t tend to show areas of cancer involvement that correlate with a patient’s symptoms.”